$IBIO Interesting!!! Novavax’s contract under the program aims to get its candidate through late-stage clinical trials. That means establishing large-scale manufacturing and making 100 million doses “in parallel” with those trials, Erck said in an interview earlier this month. “You have to start building manufacturing capacity at large scale.” And still, the company will need more help, Erck said. “This contract covers 100 million doses, but what we need is 500 million doses.” Specifically, he said, Novavax needs an additional contract for a product purchase next year, and partners to help the company distribute the product globally, in addition to those already on board. That work will also involve the traditional vaccine distribution network, but “we also have an interest in making our vaccine available globally,” and those discussions have started, Erck said.